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Introduction: The pathophysiology of endotoxemia-induced acute kidney injury (AKI) is characterized by an intense
activation of the host immune system and renal resident cells by lipopolysaccharide (LPS) and derived proinflammatory
products. However, the occurrence of renal fibrosis in this setting has been poorly investigated. The aim of the present
study was to investigate the possible association between endothelial dysfunction and acute development of tissue
fibrosis in a swine model of LPS-induced AKI. Moreover, we studied the possible effects of coupled plasma filtration
adsorption (CPFA) in this setting.
Methods: After 9 hours from LPS infusion and 6 hours of CPFA treatment, histologic and biochemical changes were
analyzed in pigs. Apoptosis and endothelial dysfunction were assessed on renal biopsies. The levels of LPS-binding
protein (LBP) were quantified with enzyme-linked immunosorbent assay (ELISA). Endothelial cells (ECs) were stimulated
in vitro with LPS and cultured in the presence of swine sera and were analyzed with FACS and real-time RT-PCR.
Results: In a swine model of LPS-induced AKI, we observed that acute tubulointerstitial fibrosis occurred within 9 hours
from LPS injection. Acute fibrosis was associated with dysfunctional alpha-smooth muscle actin (α-SMA)+ ECs characterized
by active proliferation (Ki-67+) without apoptosis (caspase-3-). LPS led to EC dysfunction in vitro with significant vimentin
and N-cadherin expression and increased collagen I mRNA synthesis. Therapeutic intervention by citrate-based CPFA
significantly prevented acute fibrosis in endotoxemic animals, by preserving the EC phenotype in both peritubular
capillaries and renal arteries. We found that the removal of LBP from plasma was crucial to eliminate the effects of LPS
on EC dysfunction, by blocking LPS-induced collagen I production.
Conclusions: Our data indicate that EC dysfunction might be pivotal in the acute development of tubulointerstitial
fibrosis in LPS-induced AKI. Selective removal of the LPS adaptor protein LBP might represent a future therapeutic option
to prevent EC dysfunction and tissue fibrosis in endotoxemia-induced AKI.Introduction
Sepsis is a complex disease arising from the host response
to an overwhelming infection. Gram-negative bacteria and
the components of their walls, in particular the lipid
A-containing lipopolysaccharide (LPS), play a major role in
the pathogenesis of sepsis [1]. As in Gram-negative sepsis,* Correspondence: loreto.gesualdo@uniba.it
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article, unless otherwise stated.during endotoxemia, LPS induces uncontrolled cytokines
release, activation of coagulation on endothelial cells (ECs)
[2] leading to shock, multiple organ damage, and even
death [3]. During sepsis and endotoxemia, acute kidney
injury (AKI) is a frequent complication [2].
The pathophysiology of sepsis-induced AKI is charac-
terized by intrarenal hemodynamic changes, EC dysfunction,
infiltration of inflammatory cells in renal parenchyma,
intraglomerular thrombosis, and tubular obstruction
with necrotic/apoptotic-derived cellular debris [2]. EC
dysfunction [4,5] is a term that includes a number oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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including transition from a quiescent to an activated state
[6]. The activation of EC [7,8] leads to an increased
expression of cell-adhesion molecules such as ICAM-1,
and chemokines with subsequent enhancement of
EC-leukocytes interaction [9]. Interestingly, recent evidence
highlighted the direct implications of EC dysfunction in
mediating tissue fibrosis by different mechanisms [9].
EC [10] and tubular epithelial cells [11] are activated by
LPS through the Toll-like receptor-4 (TLR-4), myeloid
differentiation protein-2 (MD-2), and CD14 complex. LPS
activation on EC induces both proinflammatory and
cytoprotective effects [12]. Conversely, renal tubular
epithelial cells undergo apoptotic and necrotic processes
[13] when activated by LPS. Extracorporeal treatments
based on plasma adsorption have been proposed as a
possible approach to modify the course of sepsis-induced
AKI, interfering with the imbalance between pro- and
antiinflammatory factors induced by LPS [1,2,14].
In this study, we investigated the possible association
between EC dysfunction and acute development of tissue
fibrosis in a swine model of LPS-induced AKI, and we
tested whether citrate-based coupled plasma filtration
adsorption (CPFA) therapy might be beneficial in this
model.
Methods
Animal model
The animal model of endotoxemia was developed in
domestic swine at the Faculty of Veterinary Medicine,
Bari University, after approval by the ethical committee
of the Italian Ministry of Education, University, and
Research (MIUR). Female pigs, with a body weight of
58.4 ± 14.7 kg, 6.8 ± 07 months old, were fasted for
24 hours before the experiment. All animals were
premedicated with an intramuscular mixture of Telazol
(tiletamine + zolazepam) 4 to 5 mg/kg and atropine
0.04 mg/kg (atropine sulfate 0.1%; ATI, Bologna, Italy).
After 20 minutes, a 20-gauge catheter was introduced into
the auricular vein of the right ear, and an infusion of
Ringer lactate solution (LRS) was started (10 ml/kg/h).
General anesthesia was induced with an intravenous
infusion of IV fentanyl (5 μg/kg) (Fentanest; Pharmacia &
Upjohn, Milano, Italy) followed by propofol (3 to 5 mg/kg
to effect) and maintained with a constant-rate infusion of
propofol (5 to 8 mg/kg/h) and fentanyl (10 μg/kg/h).
Additional boluses of fentanyl and propofol were given as
needed. After induction of anesthesia, animals were
endotracheally intubated by a cuffed tube and connected
to a breathing circuit. After intubation, the pigs received
an intermittent positive pressure ventilation (IPPV) with a
tidal volume and respiratory rate set to maintain end-tidal
CO2 partial pressure (PETCO2) between 30 and 40 mm Hg.
All animals received 40% of oxygen through the breathingcircuit (Ohmeda 7850 ventilator; Datex Ohmeda, Helsinki,
Finland).
An 18-gauge catheter was inserted into the left carotid
artery for arterial blood sampling and systemic blood
pressure measurement. A triple-lumen 16-gauge central
venous catheter was advanced into the left jugular vein
for drugs and LRS administration, and for recording of
central venous pressure.
Body temperature was maintained by a thermoregulated
blanket control unit. A urinary catheter was placed in all
animals for the measurement of urine output and for
urinalysis. Electrocardiogram (ECG), pulse oximetry,
capnography, airways pressures and tidal volume, blood
glucose, and lactate were also monitored.
We randomized the animals into four groups: control
(CTR, n = 7), CPFA (CPFA-treated healthy pigs, n = 7), LPS
(endotoxemic pigs, n = 7), and LPS CPFA (CPFA-treated
endotoxemic pigs, n = 7).
Through the previously isolated venous access, in
LPS and LPS CPFA groups, 10 ml of a saline solution
containing 300 μg/kg of LPS (lipopolisaccharide membrane
of Escherichia coli) was infused. CTR and CPFA pigs
received 10 ml of sterile saline solution.
CPFA was performed with plasma filter (input: 25 μm
polypropylene; output: 25 μm polypropylene +5 μm
nylon; Bellco, Mirandola, Italy) and adsorption cartridge
(styrene resin with macroporous structure, 30 nm;
Mediasorb Bellco). Blood flow rate (Qb) was included
between 100 ml/min and 250 ml/min, ultrafiltration
rate at 35 ml/kg/h, and plasma filtration at 30 ml/min. The
local citrate anticoagulation protocol was validated by
using Lynda equipment. Predilution citrate was infused
(citrate bag: Na +136 mM, citrate 10 mm, citric acid
2 mM). Calcium was infused in postdilution (Na +139 mM,
K +1.5 mM, Ca2+ 2 mM, HCO3, 35 mM, and glucose,
5.55 mM) [15]. During the CPFA session, blood samples
were collected to control calcium systemic levels at 1.05 to
1.2 mM and within the circuit at 0.2 to 0.3 mM. The
duration of treatment was 6 hours. During treatment,
hemodynamic and respiratory parameters were continu-
ously monitored. Animals were killed after 9 hours from
LPS/saline infusion or after 6 hours CPFA treatment (T9)
with an overdose of IV thiopental, immediately followed by
a 10-ml IV bolus of an oversaturated solution of potassium
chloride (Sigma-Aldrich, Gillingham, UK).
Collection of samples
A renal biopsy was performed at the start of experimental
procedure (T0). Multiple biopsies were then obtained
at different intervals from saline or LPS infusion and
at death (T9).
A portion of each biopsy specimen was immediately
snap-frozen in Optimal Cutting Temperature (OCT,
Tissuetek) medium and stored in liquid nitrogen. Another
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and embedded in paraffin by using standard procedures.
Urine samples were collected from all animals, and
urinary output was measured and recorded every hour.
Swine sera were collected at T0, at intermediate time
points, and at T9 from an arterial blood catheter. Plasma
samples were drawn from a CPFA circuit at the inlet
(plasma pre-cartridge) and outlet (plasma post-cartridge)
of the adsorption cartridge 1 hour after installation
(T4), at different intervals and finally after 6 hours of
treatment (T9). Sera and plasma samples were stored
at −80°C until their use.
Renal-function measurements
Serum Kidney Injury Molecule-1 (KIM-1) and Cystatin C
measurements were performed with commercially
available enzyme-linked immunoassays (ELISAs; Uscn
Life Science Inc, Wuhan, Hubei, China) according to
manufacturer’s instructions.
Cell culture
Immortalized human umbilical vein EC line (EA.hy926),
obtained from American Type Culture Collection (ATCC,
Rockville, MD, USA) were cultured in DMEM high-glucose
medium supplemented with 10% FBS, 100 U/ml penicillin,
0.1 mg/ml streptomycin, 2 mM L-glutamine (Sigma
Aldrich) at 37°C in an atmosphere of 5% CO2. When cells
became confluent, they were stimulated for 24 hours with
LPS 2 μg/ml and 4 μg/ml and were incubated for 12 hours
in the presence of 1% of different swine sera with/without
LPS Binding Protein (LBP), 9 μg/ml.
Masson trichrome staining
Two-μm-thick sections of swine paraffin-embedded renal
biopsies were deparaffinized and rehydrated with alcohol.
Then they were washed with distillated water and incubated
with Bouin solution overnight at room temperature. The
slides were stained in Weigert iron hematoxylin solution for
6 minutes. After that, they were washed and stained with
scarlet-acid fuchsin solution for 15 minutes. The sections
were differentiated in 1% acetic acid solution for 1 minute,
and then they were immersed in phosphomolybdic acid for
4 minutes. They were again differentiated in acetic
acid solution and immersed in green-light solution 2%
for 5 minutes. After differentiation with acetic acid
solution, slides were dehydrated, cleared in xylene,
and mounted with Eukitt.
Digital slides were then acquired with the Aperio
ScanScope CS2 device (Aperio Technologies, Vista, CA,
USA) with 20× magnification. Green-stained area was
quantified by using Adobe Photoshop software and
expressed as positive pixel/total pixel by two independent
observers blinded to the origin of the slides. The finalquantification was the mean of the two measures. In no
case was interobserver variability higher than 20%.
Confocal laser scanning microscopy
Swine paraffin-embedded renal sections were stained or
double stained for α-SMA (Santa Cruz Biotechnologies,
Santa Cruz, CA, USA), CD31 (Abcam, Cambridge, MA,
USA), and Ki-67 (Novus Biologicals, CA, USA). All the
antibodies cross-react with pig tissue. Tissue sections
were deparaffinized through xylene and alcohol and
underwent epitope retrieval through three microwave
(750 W) cycles of 5 minutes in citrate buffer (pH = 6).
Then they were incubated with specific blocking solution,
primary antibodies (anti-α-SMA 1:100, anti-CD31 1:30,
anti-Ki-67 1:50) and the corresponding secondary
antibodies (Alexa Fluor 488 goat anti-mouse; AlexaFluor
555 goat anti-rabbit, and AlexaFluor 488 goat anti-rabbit,
Molecular Probes, Eugene, OR, USA). All sections were
counterstained with TO-PRO-3 (Molecular Probes) and
mounted with fluoromount. Negative controls were
prepared by omitting the primary antibody.
Image acquisition was performed with confocal
microscope Leica TCS SP2 (Leica, Wetzlar, Germany).
Fluorescence signals were quantified by confocal micro-
scope Leica TCS SP2 software and expressed as area
fraction (percentage). The number of CD31+/α-SMA+
and Ki-67+/CD31+ cells was quantified in at least
10 high-power (×630) fields (HPF)/sections by two
independent observers blinded to the origin of the
slides. The final counts were the mean of the two
measures. In no case was interobserver variability
higher than 20%.
Caspase-3 immunohistochemistry
After epitope unmasking through microwave and citrate
buffer, renal tissues were washed with distillated water
and incubated with H2O2 (3%) for 7 minutes at room
temperature. They were permeabilized with Triton 0.25%
for 5 minutes and blocked with protein block solution
(Dako, Glostrup, Denmark) for 10 minutes. Then sections
were incubated with the primary antibody (Caspase-3,
Novus Biologicals; diluted 1:50) and detected by the
Peroxidase/DAB Dako Real EnVision Detection System,
according to manufacturer’s instructions (Dako). The
peroxidase reaction was shown by a brown precipitate,
counterstained with Mayers hematoxylin (blue), and
mounted with Glycergel (DakoCytomation, Carpinteria,
CA, USA). Negative controls were prepared incubating
sections with the blocking solution and then control
irrelevant antibody. Digital images were scanned by
Aperio ScanScope CS2 device (Aperio Technologies)
by two independent observers blinded to the origin of
the slides. The selected regions of digital slides were
analyzed with the algorithm for analysis of nuclear signal
Figure 1 (See legend on next page.)
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Figure 1 LPS-induced AKI is associated with early development of tissue fibrosis. In a swine model of LPS-induced AKI, Masson trichrome
staining (A) revealed extensive collagen deposition at the interstitial level (thin black arrow), along capillaries (zoomed image), and diffuse
glomerular thrombi (thick black arrow) after 9 hours from LPS infusion compared with T0 and T9 of the control group. The pictures are displayed
at 4× magnification (A, first line) and 10× magnification (A, second line). (C) In basal condition, no α-SMA+ cells (green) were localized in the
interstitium and within glomeruli (white arrows). A dramatic increase in α-SMA expression was observed at tubulointerstitial level and within
glomeruli and the Bowman capsule (white arrow). An early tubulointerstitial expression of α-SMA was found already at 1 hour with LPS injection.
Magnification 630×. To-pro 3 was used to counterstain nuclei (blue). The quantitative analyses of Masson trichrome (B) and α-SMA staining
(D) were obtained as described in the Methods section and expressed as median ± IQR of at least five independent pigs for each group. The ELISA
tests (E, F) showed a significant increase of KIM-1 and cystatin C in swine sera at 6 and 9 hours from LPS administration compared with T0.
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Technologies) to measure both staining intensity and
percentage of positive cells. For each region, the algorithm
identified the total number of tubular analyzed cells, and
the percentage of cells with absent (0) to strong (3+)
nuclear signal. The percentages of positive cells were
indicated by the Aperio Software.
Cell-growth determination kit
Cultured ECs were seeded (2 × 104 cells per well) on
96 wells in 100 μl of complete culture medium.
Cells were treated with LPS, 2 μg/ml, and LPS, 4 μg/ml,
for 24 hours. EC proliferation was evaluated by measuring
the activity of living cells via mitochondrial dehydrogenase
activity by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetra-
zolium bromide or Methylthiazol Tetrazolium (MTT)
(Sigma Aldrich).
After 24 hours of stimulation, ECs were incubated with
10% MTT reagent in DMEM for 4 hours. As indicated in
manufacturer’s instructions (Sigma Aldrich), mitochondrial
dehydrogenases of active and viable EC converted the
MTT in formazan crystals. The addition of 100 μl
isopropanol per plate dissolved the crystal, generating
a purple solution that was measured by spectrophotometer
at 570 nm by a microplate reader (DV990BV6,GIO. DE
VITA E C. S.R.L, Rome, Italy). The absorbances obtained
were compared with an appropriate absorbance/cell
number curve. Three independent experiments were
performed.
Detection of viable and apoptotic ECs with
flow-cytometry analysis
Apoptotic and viable ECs were evaluated with Annexin
V(Ann V)- Fluorescein isothiocyanate (FITC) and propi-
dium iodide (PI) (Beckman Coulter). After 24 hours of
LPS 2 μg/ml and 4 μg/ml stimulation, ECs were washed
twice with PBS and were removed with trypsin-EDTA.
Then 5 × 105 cells were resuspended in 100 μl of ice-cold
PBS binding buffer 1× (Beckman Coulter) and incubated
with annexin V-FITC and PI for 15 minutes at 4°C in the
dark. Finally, 400 μl of PBS binding buffer 1× was added
to each tube without washing and analyzed with FC500
(Beckman Coulter) and Kaluza software. This assay wasdone in triplicate and ECs stimulated for 24 hours with
H2O2, 100 μM, as internal positive control.
Immunophenotypic analysis
EC phenotype was analyzed with surface staining with
the FITC-conjugated anti-CD31 (Miltenyi Biotec),
Allophycocyanin (APC)- conjugated anti-CD31 (Miltenyi
Biotec), phycoerythrin (PE)- conjugated anti-VE-cadherin
(Biolegend, San Diego, CA, USA), PE-conjugated anti-N-
cadherin (Biolegend), and intracellular staining with
unconjugated anti-vimentin antibody (Abcam) and uncon-
jugated anti-FSP-1 antibody (Abcam).
At the end of the EC stimulation with LPS or swine sera,
cells were washed twice with PBS and were removed with
PBS-EDTA 2 mM and trypsin 0.001×. For surface
staining, ECs were resuspended in flow cytometry
(FACS) buffer (phosphate-buffered saline, pH 7.2, 0.2%
bovine serum albumin, and 0.02% sodium azide) and
incubated with FCR blocking reagent (Miltenyi Biotec)
for 10 minutes at room temperature.
After blocking incubation, surface markers were added
for 15 minutes at 4°C. Then cells were washed with the
FACS buffer and were resuspended in each tube with
500 μl of FACS buffer for FACS analysis. Intracellular
staining was preceded by fixation and permeabilization
with IntraPrep kit (Instrumentation Laboratory) and
incubation for unconjugated primary antibody 25 minutes
at 4°C. Cells were then washed and labeled with secondary
Antibody AlexaFluor 488 (Molecular Probes) for 25 minutes
at 4°C. Finally, cells were washed twice and resuspended in
FACS buffer for acquisition.
Data were obtained by using a FC500 (Beckman Coulter)
flow cytometer and analyzed withKaluza software. Three
independent experiments were performed. The area of
positivity was determined by using an isotype-matched
mAb, and in total, 104 events for each sample were acquired.
LBP plasma and serum levels
LBP levels were determined in sera and pre/post-cartridge
plasma by a commercially available enzyme-linked
immunosorbent assay (ELISA; Enzo Life Sciences,
Farmingdale, NY, USA) according to manufacturer’s
instructions.
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Total RNA was isolated with miRNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions, and quantified by NanoDrop ND-1000 Spec-
trophotometer (NanoDrop Technologies, Inc. Wilmington,
DE, USA); its quality was assessed with electrophoresis on
the agarose gel (1%). One-half microgram of total RNA was
used in a reverse transcription (RT) reaction by using the
QuantiTect reverse transcription Kit (Qiagen) according to
the manufacturer’s instructions. Quantitative real-time
(RT)-PCR was performed on an iCycler Thermal Cycler
(Bio-Rad Laboratories, Hercules, CA, USA) by using
Collagen I primers (Rev 5′-CAGGGAAGCCTCTC
TCTCCT-3′; For 5′-ACGTCCTGGTCAAGTTGGTC-3′,
Invitrogen) in combination with SYBR Green dye. The
relative amounts of Collagen I mRNA were normalized to
GAPDH mRNA as the housekeeping gene.
Statistical analysis
Data were expressed as median ± interquartile range
(IQR) and compared with a Mann–Whitney test. For FACS
analysis, MTT assay and real-time PCR, data were shownFigure 2 Recovery of hypotension, oligoanuria, and renal function in
after 3 hours of LPS infusion. CPFA treatment restored blood pressure to basa
AKI. Urinary output was significantly reversed after 6 hours of CPFA treatment
(D) at 6 and 9 hours from LPS infusion.as mean ± standard deviation (SD) or standard error of the
mean (SEM) and compared with the Student t test or
ANOVA, as appropriate. A P value <0.05 was considered
statistically significant. All analyses were performed by
using GraphPad Prism 5.0 (GraphPad software, Inc., San
Diego, CA, USA).
Results
Endotoxemia-induced oliguric kidney injury is associated
with early development of tissue fibrosis
To characterize the possible development of renal fibrosis,
we first analyzed kidney biopsies with Masson trichrome
staining (Figure 1A). Control animals did not present
significant tubulointerstitial and glomerular collagen
deposits both at T0 and 9 hours after the infusion of
control saline solution. On the contrary, LPS infusion
induced an extensive collagen deposition at tubulointersti-
tial level, in particular, surrounding peritubular capillaries.
Endotoxemic pigs showed diffuse glomerular thrombi
and tubular vacuolization that were not detectable in
control animals. Quantification of stainings indicated
that LPS-treated animals had a statistically significantendotoxemic animals. (A) Endotoxemic pigs developed hypotension
l condition. (B) Presence of oligoanuria was a clear sign of LPS-induced
. CPFA treatment significantly reduced serum KIM-1 (C) and cystatin C
Figure 3 (See legend on next page.)
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Figure 3 Characterization of renal EC dysfunction in vivo. ECs were double-stained for CD31 (red) and α-SMA marker (green) further to
demonstrate the occurrence of endothelial dysfunction. In renal vessels of endotoxemic tissue (C, dotted white arrow), CD31+EC expressed α-SMA
marker and migrated from the intima to the media of the vessel wall (E, zoomed image), in otherwise basal condition (A, dotted white arrow). In the
interstitium of T9 control pig (A, B) CD31+/α-SMA+ cells were rarely detectable. After 9 hours from LPS infusion, the number of these cells increased
dramatically within glomeruli (C, white arrows) and interstitium (D, white arrows). Zoomed image of EC (F) co-expressing CD31 and α-SMA in
endotoxemic tissue. Results are expressed as median ± IQR of the numbers of CD31+/α-SMA+ cells/HPF of at least five independent pigs for each
group (G). Magnification, 630×. To-pro 3 was used to counterstain nuclei (blue).
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(Figure 1B).
Next we investigated the expression of α-SMA, a
marker of activated myofibroblasts. We detected a
significant expansion of α-SMA+ cells in endotoxemic
pigs, particularly at tubulointerstitial level (Figure 1C)
and within glomeruli. As expected, in normal conditions,
this marker was almost absent both at tubulointerstitial
and glomerular level; α-SMA was associated only with
smooth muscle cells of renal arteries. Interestingly,
tubulointerstitial α-SMA expression was present already
1 hour after LPS infusion. The overall increase in α-SMA
expression (D) in endotoxemic animals was statistically
significant when compared with controls.
Finally, we investigated whether the development of
acute fibrosis was associated with the expression of
biomarkers of tubular damage (Figure 1E, F). After 6
and 9 hours from LPS injection, endotoxemic animals
showed a significant increase in serum levels of KIM-1
and cystatin C, compared with the basal condition. On the
contrary, serum creatinine was similar in endotoxemic
pigs and controls (data not shown).
In addition, LPS-treated pigs developed hypotension
(Figure 2A). Considering the normal urinary output in pigs
(5 to 30 ml/kg/h), the urinary output in our model during
endotoxemia reached a value of 1.5 ml/kg/h, indicating the
occurrence of oliguric kidney injury (Figure 2B).
Association of endothelial dysfunction with acute
development of renal fibrosis
We then performed a double immunofluorescence staining
for EC marker CD31 and α-SMA. In control condition, EC
showed a clear distribution of CD31 both in the intima of
the renal arteries (Figure 3A) and in peritubular capillaries
(Figure 3B). After LPS infusion, the phenotype of renal EC
dramatically changed. In renal vessels (Figure 3C, E),
CD31+ EC acquired α-SMA and could be detected in
the media of the vascular wall, indicating a possible
migration from intima to media (Figure 3E). Moreover, we
found a significant increase in peritubular α-SMA+ EC
(Figure 3D). The colocalization of these two markers on
ECs was statistically significant in LPS-treated animals
(Figure 3G) and occurred particularly at the tubulointer-
stitial level (Figure 3F).Phenotypic characterization of dysfunctional ECs in
endotoxemia
Next we wanted to characterize the occurrence of apoptosis
in dysfunctional ECs by caspase-3 staining. Caspase-3
expression was barely detectable in vehicle-treated animals
(Figure 4A-C), whereas renal tubular epithelial cells of
endotoxemic pigs were strongly positive (Figure 4F). The
difference between the two experimental conditions was sta-
tistically significant (Figure 4G). Conversely, ECs at vascular
and glomerular levels were not involved in apoptotic
processes (Figure 4D, E). In addition, we studied whether
CD31+ ECs expressed a marker of cellular proliferation.
Compared with normal conditions (Figure 4H), we found a
significant increase of Ki-67+/CD31+ ECs in endotoxemic
tissues (Figure 4I-K). Proliferating ECs in endotoxemic pigs
were significantly higher compared with controls (Figure 4L).
LPS induced EC dysfunction in vitro with collagen I mRNA
synthesis
We then investigated whether LPS could directly induce EC
dysfunction in vitro. After 24 hours of LPS activation, FACS
analysis showed that only a small percentage of ECs under-
went apoptosis (Figure 5A). By MTT cell viability assay, we
observed a significant proliferation of EC when activated by
LPS (Figure 5B). The FACS analysis showed that control
ECs presented, as expected, high levels of EC markers,
CD31 and VE-cadherin, and low levels of EC dysfunction
markers, such as N-cadherin, vimentin, and FSP-1.
After 24 hours of incubation, LPS induced a significant
reduction in CD31 and VE-cadherin expression, with a
concomitant dose-dependent increase of N-cadherin,
vimentin and FSP-1 (Figure 5C, D). Moreover, after 6 and
9 hours from LPS exposure, α-SMA+ ECs were barely
detectable (data not shown).
Finally, LPS incubation induced a significant increase in
collagen I mRNA synthesis, indicating that EC dysfunc-
tion resulted in active contribution to the synthesis of
extracellular matrix components (Figure 5E).
Prevention of LPS-induced renal fibrosis by citrate-based
CPFA treatment
Next we tested whether CPFA might counteract the
detrimental effects of LPS and the development of renal
fibrosis in vivo.
Figure 4 (See legend on next page.)
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Figure 4 Characterization of dysfunctional ECs in endotoxemia. Immunohistochemical analysis for caspase-3 showed rare apoptotic EC in
endotoxemic pigs within glomeruli (D), at vascular (E) and peritubular levels (F, zoomed image, thin black arrow). Moreover, an increased number
of tubular cells underwent apoptosis (F, zoomed image, thick black arrow). Caspase-3 nuclear expression in tubular cells (G) was analyzed as
reported in the Methods section and expressed as median ± IQR of at least five independent pigs for each group. Magnification 10× (A, B, D, E)
and 20× (C, F). Double immunofluorescence analysis (CD31 red; Ki-67 green) revealed Ki-67+/CD31+ proliferating ECs in endotoxemic pigs (I)
compared with the T9 control group (H). Single-color images (J, K) underlined the co-localization of C31 (red J) and Ki-67 (green K) markers on
ECs. Results are expressed as median ± IQR of the numbers of Ki-67+/CD31+ cells/HPF of at least five independent pigs for each group (L).
Magnification, 630×. To-pro 3 was used to counterstain nuclei (blue).
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were treated for 6 hours with CPFA; renal biopsies were
performed at T9. Masson trichrome staining showed
that treatment significantly reduced renal fibrosis, as
shown by decreased collagen deposits compared with
endotoxemic pigs (Figure 6A, B). The reduction of
extracellular matrix deposits was particularly evident at
peritubular capillary level. We observed very limited
glomerular thrombi compared with untreated animals. The
induction of peritubular α-SMA expression (Figure 6C, D)
and tubular apoptosis (Figure 6E, F) were also significantly
hampered in treated pigs. Moreover, arterial blood pressure
and urinary output significantly improved after 6 hours of
treatment (Figure 2A, B). Finally, the downregulation of
serum biomarkers of renal injury, KIM-1 and cystatin C,
demonstrated a protective effect of CPFA on tubular
damage (Figure 2C, D).
Inhibition of EC dysfunction by CPFA treatment
Then we investigated the effects of CPFA on EC dysfunc-
tion. As indicated in Figure 7A, renal arteries showed a
preservation of CD31 expression on vessel intima and
the absence of CD31+/α-SMA+ cells in the vessel media
compared with endotoxemic pigs. In accordance, the
number of dysfunctional CD31+/α-SMA+ cells in the
tubulointerstitium of endotoxemic pigs was significantly
reduced by CPFA treatment (Figure 7B).
Removal of LPS-binding protein from plasma by CPFA
treatment
We then investigated whether the protective effect of
CPFA treatment was due to possible modulation of LBP,
a soluble compound of the LPS/TLR-4 complex. The
serum levels of LBP, an acute-phase protein, significantly
increased after 9 hours of LPS infusion compared with
controls (Figure 8A). Interestingly, CPFA-treated pigs
presented a dramatic reduction in serum LBP levels.
When we measured the concentration of LBP before
and after the plasma passage throughout the sorbent
cartridge at different time points, we observed a significant
decrease in LBP concentration in the plasma effluent from
the sorbent cartridge already 1 hour after starting treat-
ment (Figure 8B, T4). After 6 hours of treatment, LBP
concentration further decreased before and after thesorbent cartridge, reaching very low levels in the post-
cartridge sample (Figure 8B, T9). Despite the removal of
serum LBP, endotoxin levels remained unchanged (LAL
Test, data not shown).
LBP is pivotal in LPS-mediated endothelial dysfunction in
sepsis
Finally, we investigated whether the removal of LBP
by CPFA was critical in mediating EC dysfunction in
LPS-treated animals. We cultured ECs in the presence of
different pig sera for 12 hours. FACS analysis (Figure 8C, D)
showed that serum from endotoxemic pigs treated
with CPFA prevented EC dysfunction, with higher CD31
and VE-cadherin expression compared with endotoxemic
pigs. In accordance, CPFA treatment maintained the
expression of the dysfunctional markers N-cadherin and
vimentin at low levels. Remarkably, the addition of
exogenous LBP in sera from CPFA-treated endotoxemic
pigs induced EC dysfunction like that of the untreated
endotoxemic animals sera.
When we quantified the relative expression of all the
markers tested, we found that the LBP supplementation
completely reversed the effects of CPFA-treated endotoxe-
mic pig serum, leading to EC dysfunction (Figure 8D).
Exogenous LBP was also capable of restoring the capacity
of CPFA-treated endotoxemic sera to induce collagen I
mRNA synthesis in ECs (Figure 8E).
Discussion
In this study, we demonstrated that endotoxemia-induced
oliguric kidney injury is characterized by an acute develop-
ment of renal fibrosis, associated with endothelial dysfunc-
tion. In our model, CPFA treatment could significantly
limit renal fibrosis and EC dysfunction by an efficient
removal of the LPS-adaptor protein LBP.
Sepsis has been well recognized as a systemic inflamma-
tory response to an active infectious process in the host
[16], which frequently leads to multiorgan dysfunction,
shock, and death [3]. Among the several disorders
encountered in sepsis, the incidence of AKI remains very
high, and an appropriate therapeutic strategy has not
been identified [17]. The pathophysiology of AKI in
sepsis is very different from nonseptic AKI [18] and
is characterized by alterations in the homeostasis of
Figure 5 (See legend on next page.)
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Figure 5 LPS induced EC dysfunction and collagen I mRNA synthesis. Cultured ECs were incubated with LPS, 2 μg/ml, or LPS, 4 μg/ml, for
24 hours. (A) EC viability was evaluated with FACS analysis (AnnV/PI). Only a small percentage of ECs underwent apoptosis after LPS, 2 μg/ml
(8.9% ±1.6 versus basal 5. 9% ±1.2) and LPS, 4 μg/ml (7.8% ±1.6) stimulation compared with ECs treated with H2O2 100 μM for 24 hours (positive
control). (B) MTT cell-viability assay highlighted a significant proliferation of ECs after LPS, 2 μg/ml (0.720 ± 0.03 versus basal 24-hour 0.469 ± 0.004;
P = 0.03) and LPS 4 μg/ml (0.597 ± 0.03 versus basal 24 hour 0.469 ± 0.004, P = 0.04) stimulation. (C, D) FACS analysis of EC showed the phenotypic
changes induced by 24 hours of LPS stimulations. Results are expressed as mean ± SD and are representative of three independent experiments.
(E) Real-time RT-PCR revealed the mRNA expression levels of collagen I. The gene relative expression was normalized to the expression of GAPDH.
The histograms represent the mean ± SEM and are representative of three independent experiments.
Figure 6 Prevention of LPS-induced renal fibrosis by CPFA treatment. Renal biopsies after CPFA treatment showed a significant reduction in
collagen deposits (A, thin arrow), in particular along capillaries (zoomed image), and glomerular thrombi (thick arrow) compared with endotoxemic
condition. Magnification 6×. (C) Immunofluorescence analysis showed a strong expression of interstitial α-SMA (green) in endotoxemic pigs that was
dramatically decreased by CPFA treatment (white arrow). Magnification, 630×. To-pro 3 was used to counterstain nuclei (blue). (E) Caspase-3 staining
highlighted the efficacy of treatment (black arrows) in reversing LPS-induced tubular apoptosis. Magnification, 14×. The quantitative analyses of Masson
trichrome (B), α-SMA (D), and caspase-3 (F) staining were obtained as described in the Methods section and expressed as median ± IQR of at least five
independent pigs for each group.
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Figure 7 Inhibition of EC dysfunction by CPFA treatment. (A) In endotoxemic animals, the reduced CD31 (red) expression at vascular level
(dotted white arrow) was reversed after 6 hours of CPFA treatment (dotted white arrow). The increased number of CD31+/α-SMA+ cells induced
by LPS infusion (white arrows) was significantly hampered in treated pigs (white arrows). (B) Results are expressed as median ± IQR of the
numbers of CD31+/α-SMA+ cells/HPF of at least five independent animals for each group. (C) Comparison of zoomed peritubular capillaries of
endotoxemic (white arrow) and treated endotoxemic pigs (white arrow). Magnification, 630×. To-pro 3 was used to counterstain nuclei (blue).
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Sepsis-induced AKI can be driven by different mechanisms
[9]. In particular, the LPS/TLR-4 axis plays a pivotal role in
this setting [19]. When the TLR-4 pathway was blocked
in vivo, a significant protection occurred in animal models
of LPS-induced AKI [20]. Accordingly, humans lacking
myeloid differentiation protein 88 (MyD88) activity had
very limited severe infections [21]. Interestingly, LPS
could modify systemic and local cytokine production
with significant alteration in peritubular capillary networks
[19]. During sepsis, ECs may switch from a quiescent to an
activated state, more commonly defined as endothelial
dysfunction [6]. In this phase, ECs may undergo structural
changes, acquiring dysfunctional markers with a fibroblast-
like phenotype [22], with possible development of fibrosis
[23,24]. Dysfunctional ECs promoted leukocyte adhesion
and trafficking along with altered vascular tone [25],
disseminated intravascular coagulation, and glomerular
microthrombi [19,26].
After LPS binding on ECs, the TLR-4 signaling involves
the activation of the NF-kB, mitogen-activated protein
kinase (MAPK) and phosphatidylinositol 3-kinase
(PI3K)/Akt pathways that regulate the balance between cell
viability and inflammation. In particular, PI3K/Akt pathway
was identified as the principal survival signal in LPS-treated
ECs [27]. A recent study demonstrated that LPS protected
microvascular lung ECs from apoptosis [12]. Our data
confirmed that LPS-induced EC dysfunction is not
associated with apoptotic ECs both in vivo and in vitro. On
the contrary, we found a significant apoptosis of tubular
epithelial cells that occurred early, as in other animal
models [21]. In addition, our model is in line with the
histologic data obtained in sepsis patients with no evidence
of acute tubular necrosis but described an increased vacuo-
lization and flattening of the brush border [21,28].
Next to tubular damage and endothelial dysfunction, we
observed the acute development of tubulointerstitial
fibrosis. To our knowledge, the early development of
renal fibrosis in our model might be a feature of
swine, because it could be detected also in ischemia/
reperfusion-induced AKI [29], and it has never been
found in rodent models [21]. Inflammation usually
precedes fibrosis, that probably initiates as a beneficial
mechanism of repair [6]. Conversely, a persistent injury
results in a pathologic condition, typical of all progressive
renal diseases, with massive deposition of extracellularmatrix [30], tubular atrophy and dilatation, tubulointerstitial
fibrosis, glomerulosclerosis, and endothelium damage.
Our histologic data are in line with the recent evidence
regarding the role of bacteria and TLR in the pathogenesis
of fibrosis [30]. TLR-4 was recently recognized as a signifi-
cant mediator of fibroblast accumulation and tubulointersti-
tial fibrosis during renal injury [31,32]. Microbial products
might also regulate the production of TGF-β and oxidative
stress [30], with a significant impact on fibrogenesis.
Interestingly, renal EC might lead to development of
renal fibrosis by direct and indirect mechanisms [6].
Peritubular capillaries constitute the major network
supplying oxygen to the nephrons. Therefore, alterations
in renal ECs might induce progressive hypoxia of renal
tubular epithelial cells with alteration in prostaglandin
synthesis and generation of reactive oxygen species [7].
Morphologic alterations of peritubular capillaries were
strongly associated with parameters of tubulointerstitial
injury in humans [33]. Moreover, recent evidence supports
a direct effect of ECs in fibrogenesis. A particular form of
EC dysfunction is the endothelial-to-mesenchymal
transition that may lead to the generation of a certain
percentage of renal fibroblasts [24] in chronic kidney
disease [23]. In our model, dysfunctional ECs acquired
several myofibroblasts markers and produced collagen I
when activated by LPS in vitro and in vivo, therefore
acquiring multiple functions of myofibroblasts. In addition,
the development of EC dysfunction in our model in vivo
required only 9 hours, whereas 24 hours was necessary by
LPS stimulation on ECs in vitro. Interestingly, we found
transitioning CD31+/α-SMA+ ECs in the media of renal
vessels, which might have migrated from the intima.
These data are in line with other works describing
the invasiveness capacity of ECs after transition to the
mesenchymal state, a process named endothelial-to-
mesenchymal transition [24]. The reduction in CD31
staining was limited to ECs localizing only in renal vessels,
indicating the presence of different factors influencing the
activation of ECs. In this context, smooth muscle vascular
cells might be pivotal in driving the development of these
transitioning ECs, by producing interleukins, chemokines,
and growth factors [34].
Modulation of the host response to endotoxin is one
of the major therapeutic targets in sepsis-induced AKI
[35]. However, the use of immunotherapy to modify
potential sites of the LPS/TLR-4 signaling pathway showed
Figure 8 (See legend on next page.)
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Figure 8 LBP is pivotal in LPS-mediated endothelial dysfunction. (A) ELISA revealed the increased level of LBP in sera of endotoxemic
pigs comparing with the control group at T0 and T9. A considerable reduction in serum LBP levels was found after 6 hours of CPFA treatment.
(B) Plasma samples drawn from the CPFA circuit were also analyzed. A significant decrease of LBP was found in the plasma filtrate effluent from
the sorbent cartridge 1 hour after circuit installation (T4 plasma postcartridge). After 6 hours from the start of treatment, LBP levels in plasma
postcartridge (T9 plasma postcartridge) were lower than in plasma precartridge. The histograms represent the median ± IQR of at least five
independent animals for each group. (C-E) Cultured ECs were treated with sera of healthy (CTR), endotoxemic (LPS), and CPFA-treated endotoxemic
(LPS CPFA) pigs. (C, D) FACS analysis of ECs showed phenotypic changes after 12 hours of LPS sera incubation. In the presence of LPS CPFA sera, EC
preserved their phenotypes. After LBP addition in LPS CPFA sera, ECs showed phenotypic changes (LBP + LPS CPFA). (D) Results are representative of
three independent experiments. (E) The expression of collagen I was detected by real-time RT-PCR. The gene relative expression was normalized to
the expression of GAPDH. The histograms represent the mean ± SEM and are representative of three independent experiments.
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therapies have been proposed to improve outcomes of
sepsis patients [18]. Our model of LPS-induced AKI,
despite the lack of a precise dissection of the molecular
pathways described in mice, is characterized by a supportive
therapy comparable to the standard for ICU patients, which
enables us to evaluate additional benefits beyond the
conventional fluid-infusion therapy [21]. However, a
limitation in the present study is represented by the
lack of a blinded collection of tissues and biologic
samples in the different experimental conditions.
CPFA is a modality of blood purification in which
plasma circulates in a sorbent cartridge. In CPFA treat-
ment, plasma is separated from the whole blood and, after
passing through the sorbent, it is reinfused into the blood
circuit reconstituting the whole blood structure without
proinflammatory but also antiinflammatory cytokines
[17,37]. The use of citrate provides anticoagulation of the
extracorporeal-circuit blood by chelating ionized calcium
[38], with potential protective effects against endothelial
inflammation and dysfunction [39].
In our model, we observed a beneficial effect of CPFA
treatment. However, it is important to consider that because
CPFA cannot remove LPS from the circulation [37] because
of the features of the sorbet cartridge, we hypothesized that
the beneficial effects in our model might be due to the clear-
ance of another key mediator of LPS signaling. LPS-induced
cell activation in vivo depends on the presence of at least
four proteins: TLR-4, MD-2, CD14, and LBP [10,11,40-43].
LBP facilitates the uptake of LPS and LPS-CD14 complexes
into ECs and tubular cells [11]. Considering the molecular
mass of 60 kDa that was in the range of the adsorptive
capacity of the CPFA cartridge, we focused our attention on
LBP, a soluble carrier of LPS. LBP can trigger an inflamma-
tory response to chronic or recurring low LPS [10]. The
deleterious effects of LPS can occur at low concentrations
in the presence of LBP that can also facilities the uptake of
endotoxins within the cells [10,44-47].
In our study, CPFA treatment was critical to maintain
LBP at a low level with significant protective effect on
EC dysfunction, both in vivo and in vitro. These data
support the hypothesis that the possible elimination
of cytokine-modulating factors rather than cytokinesthemselves should also be considered when dealing
with these types of treatments. Therefore, considering our
data, it is possible to postulate a scenario in which a
selective removal of LBP might be sufficient to block the
detrimental effect of LPS in vivo, including LPS-mediated
systemic and local cytokines release.Conclusions
In conclusion, we demonstrated that in the early phase of
LPS-induced AKI, renal fibrosis is accompanied by α-SMA+
dysfunctional ECs. Extracorporeal treatment by CPFA
protects renal parenchyma by preventing the development
of tubulointerstitial fibrosis, tubular apoptosis, and EC
dysfunction. Finally, we identified, in the removal of LBP,
the critical factor that can eliminate the effect of LPS in our
model. Considering that renal fibrosis is pivotal in the
development of renal failure, we hypothesize that a selective
removal of LBP might represent a future therapeutic
strategy with a significant impact on short- and long-term
outcomes for patients with LPS-induced AKI.Key messages
 Endothelial dysfunction and early renal fibrosis
might have a central role in the pathogenesis of
endotoxemia-induced oliguric AKI.
 When activated by LPS, ECs proliferated and
acquired several markers of myofibroblasts,
therefore contributing to the development of fibrosis
and tissue injury.
 CPFA reduced renal fibrosis, tubular apoptosis, and
endothelial dysfunction, preserving renal tissue
damage.
 Selective removal of LBP might be sufficient to
block the detrimental effect of LPS in vivo, and
might represent a future therapeutic strategy.
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